酵素促傷口清創市場——增長、趨勢、COVID-19 的影響和預測 (2023-2028)

在預測期內，酵素促傷口清創市場預計將以約 5.3% 的複合年增長率增長。

推動市場增長的關鍵因素是糖尿病、癌症和其他自身免疫性疾病等慢性病發病率的增加，這是推動增長的主要因素之一。

根據國際糖尿病聯合會的數據，2019 年約有 4.63 億成年人患有糖尿病，到 2045 年將增加到 7 億，其中約 3.74 億患有 2 型糖尿病。患糖尿病的風險增加 糖尿病患者的增加表明慢性傷口（例如糖尿病足潰瘍）的數量增加，這促進了所研究市場的增長。 此外，政府增加研發項目投資以開發該部分的醫療保健基礎設施正在推動市場增長。 然而，嚴格的監管政策是市場增長的主要障礙。

酵素促傷口清創的市場趨勢

基於膠原酵素的酵素促傷口清創有望實現快速增長

基於膠原酵素的酵素促傷口清創術主要用於手術傷口癒合。 由於癌症手術後的疤痕較大且較深，會產生滲出液，需要定期處理。 因此，正確使用這些產品可以幫助治療大傷口，並大大降低感染風險。 因此，預計慢性病的增加將增加對酵素促傷口清創的需求，從而推動預測期內的市場增長。

此外，預計全球交通事故、燒傷和受傷等事故的增加也將推動增長。 據世界衛生組織統計，每年有 135 萬人死於交通事故。 因此，預計事故數量的增加將推動該行業的增長。

北美主導市場，預計在預測期內保持不變

在預測期內，預計北美將主導整個市場。 這一市場增長是由於主要參與者的存在、該地區慢性病和事故的高發率、完善的醫療基礎設施等因素造成的。 根據美國創傷外科醫師協會的數據，2017 年全球約有 120 萬人死亡，每年約有 3,242 人死於道路交通事故。 此外，有益的政府舉措和不斷增加的研究夥伴關係是推動市場增長的一些因素。

酵素促傷口清創市場競爭分析

酵素促傷口清創市場競爭適中，由幾家大型企業組成。 目前上市的公司包括 B. Braun Melsungen AG、ConvaTec Inc.、Smith & Nephew、Integra LifeSciences Corporation、Molnlycke Health Care AB、Healthpoint, Ltd 和 MediWound。

其他好處

• Excel 格式的市場預測 (ME) 表
• 三個月的分析師支持

內容

第一章介紹

• 調查結果
• 調查假設
• 本次調查的範圍

第二章研究方法論

第 3 章執行摘要

第四章市場動態

• 市場概覽
• 市場驅動因素
  • 慢性傷口的發生率增加
  • 事故數量增加
  • 增加技術先進的產品
• 市場製約因素
  • 嚴格的監管政策
• 波特的五力分析
  • 新進入者的威脅
  • 買方/消費者議價能力
  • 供應商的議價能力
  • 替代品的威脅
  • 競爭公司之間的敵對關係

第 5 章市場細分

• 按類型
  • 慢性傷口
  • 急性傷口
• 按產品分類
  • 膠原酵素產品
  • 木瓜蛋白酵素產品
  • 其他
• 最終用戶
  • 醫院
  • 家庭護理
  • 其他
• 按地區
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳大利亞
    • 韓國
    • 其他亞太地區
  • 中東和非洲
    • 海灣合作委員會
    • 南非
    • 其他中東和非洲地區
  • 南美洲地區
    • 巴西
    • 阿根廷
    • 其他南美洲

第六章競爭格局

• 公司簡介
  • B. Braun Melsungen AG
  • ConvaTec Inc.
  • Smith & Nephew
  • Integra LifeSciences Corporation
  • Molnlycke Health Care AB
  • Healthpoint, Ltd
  • MediWound

第7章 市場機會今後動向

The Enzymatic Wound Debridement market is projected to grow with a CAGR of nearly 5.3% over the forecast period. The major factor attributing to the growth of the market is the increase in the incidence of chronic diseases such as diabetes, cancer, and other autoimmune diseases is one of the major factors boosting growth.

According to International Diabetes Federation, roughly 463 million adults were living with diabetes in the year 2019, by 2045 this will rise to 700 million and around 374 million people are at increased risk of developing type 2 diabetes. The rising cases of diabetic people indicate the rising number of chronic wounds such as Diabetic Foot Ulcers, etc. which is augmenting the growth of the market studied. Furthermore, the growing investments in research and development programs by the government to develop the medical infrastructure in this section is boosting the market growth. However, the stringent regulatory policies is the major drawback of the market growth.

Enzymatic Wound Debridement Market Trends

Collagenase-based Enzymatic Wound Debridement Products are Expected to Witness Rapid Growth

Collagenase-based enzymatic wound debridement products are predominantly used for healing surgical wounds. Most surgical wounds after cancer surgery are relatively large and deep, which generates exudate that needs regular supervision. Thus, the proper use of these products helps handle large wounds, which substantially reduce the risk of infection. Therefore, the rising incidence of chronic diseases is anticipated to increase the demand for enzymatic wound debridement products, thereby propelling market growth over the forecast period.

Furthermore, an increasing number of accidents, such as road accidents, burns, and trauma, across the world is also projected to propel growth. According to World Health Organization, 1.35 million people die every year as a result of road traffic crashes. Thus, rise in the number of accidents is expected to boost the growth of the segment.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall market, throughout the forecast period. The market growth is due to factors such as the presence of key players, high prevalence of chronic diseases and accidents in the region, and established healthcare infrastructure. According to the American Association for the Surgery of Trauma, in 2017, around 1.2 million people died globally, accounting for deaths of around 3,242 people per day in road accidents every year. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase market growth.

Enzymatic Wound Debridement Market Competitive Analysis

The Enzymatic Wound Debridement market is moderately competitive and consists of several major players. Some of the companies which are currently present in the market are B. Braun Melsungen AG, ConvaTec Inc., Smith & Nephew, Integra LifeSciences Corporation, Molnlycke Health Care AB, Healthpoint, Ltd, MediWound.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 Study Deliverables
• 1.2 Study Assumptions
• 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Increasing Incidence of Chronic Wounds
  • 4.2.2 Increasing Number of Accidents
  • 4.2.3 Increasing Technologically Advanced Products
• 4.3 Market Restraints
  • 4.3.1 Stringent regulatory policies
• 4.4 Porter's Five Force Analysis
  • 4.4.1 Threat of New Entrants
  • 4.4.2 Bargaining Power of Buyers/Consumers
  • 4.4.3 Bargaining Power of Suppliers
  • 4.4.4 Threat of Substitute Products
  • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

• 5.1 By Type
  • 5.1.1 Chronic Wounds
  • 5.1.2 Acute Wounds
• 5.2 By Product
  • 5.2.1 Collagenase Product
  • 5.2.2 Papain Product
  • 5.2.3 Others
• 5.3 By End-User
  • 5.3.1 Hospitals
  • 5.3.2 Homecare
  • 5.3.3 Others
• 5.4 Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle-East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle-East and Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Company Profiles
  • 6.1.1 B. Braun Melsungen AG
  • 6.1.2 ConvaTec Inc.
  • 6.1.3 Smith & Nephew
  • 6.1.4 Integra LifeSciences Corporation
  • 6.1.5 Molnlycke Health Care AB
  • 6.1.6 Healthpoint, Ltd
  • 6.1.7 MediWound

7 MARKET OPPORTUNITIES AND FUTURE TRENDS